BioCentury
ARTICLE | Company News

GSK partners with Lyell to bring gene, cell therapies into solid tumors

October 9, 2019 12:04 AM UTC
Updated on Oct 11, 2019 at 12:11 AM UTC

As GSK looks to expand its cell and gene therapy pipeline, the pharma has partnered with Lyell to take the modalities into solid tumors by improving T cell functionality and manufacturing.

Lyell Immunopharma Inc. is focused on delaying T cell exhaustion to enhance initial response rates in solid tumor cancers and prevent relapses due to loss of T cell functionality. ...